CN110663959A - 一种供失眠人群食用的含肽组合物及应用 - Google Patents
一种供失眠人群食用的含肽组合物及应用 Download PDFInfo
- Publication number
- CN110663959A CN110663959A CN201911061567.9A CN201911061567A CN110663959A CN 110663959 A CN110663959 A CN 110663959A CN 201911061567 A CN201911061567 A CN 201911061567A CN 110663959 A CN110663959 A CN 110663959A
- Authority
- CN
- China
- Prior art keywords
- powder
- peptide
- containing composition
- insomnia
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 46
- 206010022437 insomnia Diseases 0.000 title claims abstract description 43
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 34
- 239000000843 powder Substances 0.000 claims abstract description 76
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 36
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 36
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 19
- 235000020234 walnut Nutrition 0.000 claims abstract description 19
- 235000009496 Juglans regia Nutrition 0.000 claims abstract description 17
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 14
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 14
- 235000007215 black sesame Nutrition 0.000 claims abstract description 12
- 241000283690 Bos taurus Species 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 4
- 241000758789 Juglans Species 0.000 claims description 16
- 239000011782 vitamin Substances 0.000 claims description 10
- 229940088594 vitamin Drugs 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 10
- 235000013343 vitamin Nutrition 0.000 claims description 10
- 235000003599 food sweetener Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000003765 sweetening agent Substances 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 5
- 206010033557 Palpitations Diseases 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 241000758791 Juglandaceae Species 0.000 claims description 2
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 239000004365 Protease Substances 0.000 claims description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000013373 food additive Nutrition 0.000 claims description 2
- 239000002778 food additive Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 240000007049 Juglans regia Species 0.000 abstract 1
- 230000007958 sleep Effects 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000015278 beef Nutrition 0.000 description 6
- -1 diphenhydramine) Chemical compound 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000003860 sleep quality Effects 0.000 description 5
- 206010062519 Poor quality sleep Diseases 0.000 description 4
- 240000008866 Ziziphus nummularia Species 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- GBBSUAFBMRNDJC-MRXNPFEDSA-N (5R)-zopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-MRXNPFEDSA-N 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960001578 eszopiclone Drugs 0.000 description 3
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 3
- 230000000147 hypnotic effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229960001475 zolpidem Drugs 0.000 description 3
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 3
- 229960000820 zopiclone Drugs 0.000 description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- YLXDSYKOBKBWJQ-LBPRGKRZSA-N N-[2-[(8S)-2,6,7,8-tetrahydro-1H-cyclopenta[e]benzofuran-8-yl]ethyl]propanamide Chemical compound C1=C2OCCC2=C2[C@H](CCNC(=O)CC)CCC2=C1 YLXDSYKOBKBWJQ-LBPRGKRZSA-N 0.000 description 2
- IKMPWMZBZSAONZ-UHFFFAOYSA-N Quazepam Chemical compound FC1=CC=CC=C1C1=NCC(=S)N(CC(F)(F)F)C2=CC=C(Cl)C=C12 IKMPWMZBZSAONZ-UHFFFAOYSA-N 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 208000010340 Sleep Deprivation Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229960002629 agomelatine Drugs 0.000 description 2
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 2
- 229960004538 alprazolam Drugs 0.000 description 2
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960002336 estazolam Drugs 0.000 description 2
- CDCHDCWJMGXXRH-UHFFFAOYSA-N estazolam Chemical compound C=1C(Cl)=CC=C(N2C=NN=C2CN=2)C=1C=2C1=CC=CC=C1 CDCHDCWJMGXXRH-UHFFFAOYSA-N 0.000 description 2
- 230000008717 functional decline Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 229960001964 quazepam Drugs 0.000 description 2
- 229960001150 ramelteon Drugs 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 229960003188 temazepam Drugs 0.000 description 2
- 229960003386 triazolam Drugs 0.000 description 2
- JOFWLTCLBGQGBO-UHFFFAOYSA-N triazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1Cl JOFWLTCLBGQGBO-UHFFFAOYSA-N 0.000 description 2
- 229960004010 zaleplon Drugs 0.000 description 2
- HUNXMJYCHXQEGX-UHFFFAOYSA-N zaleplon Chemical compound CCN(C(C)=O)C1=CC=CC(C=2N3N=CC(=C3N=CC=2)C#N)=C1 HUNXMJYCHXQEGX-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- PUGVROXLRUQCAF-UHFFFAOYSA-N Flurazepam monohydrochloride Chemical compound Cl.N=1CC(=O)N(CCN(CC)CC)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1F PUGVROXLRUQCAF-UHFFFAOYSA-N 0.000 description 1
- 102000004300 GABA-A Receptors Human genes 0.000 description 1
- 108090000839 GABA-A Receptors Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940053999 hypnotics and sedatives melatonin receptor agonists Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960000660 tasimelteon Drugs 0.000 description 1
- PTOIAAWZLUQTIO-GXFFZTMASA-N tasimelteon Chemical compound CCC(=O)NC[C@@H]1C[C@H]1C1=CC=CC2=C1CCO2 PTOIAAWZLUQTIO-GXFFZTMASA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000020767 valerian extract Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明属于保健食品、功能性食品技术领域，具体涉及一种供失眠人群食用的含肽组合物及其应用。本发明所述组合物以牛骨低聚肽粉、酸枣仁粉、黑芝麻粉、龙眼肉粉、核桃低聚肽粉为主要成分，辅以辅料制备成一种供失眠人群食用的含肽组合物，所述组合物具有宁心安神的功效，改善心悸不安、失眠方面的效果显著，可用于制备辅助改善心悸不安、失眠的产品。
Description
技术领域
本发明属于保健食品、功能性食品技术领域，具体涉及一种供失眠人群食用的含肽组合物及其应用。
背景技术
失眠是指无法入睡或无法保持睡眠状态，导致睡眠不足。又称入睡和维持睡眠障碍，为各种原因引起入睡困难、睡眠深度或频度过短、早醒及睡眠时间不足或质量差等，是一种常见病。失眠按病因可划分为原发性和继发性两类。原发性失眠通常缺少明确病因，或在排除可能引起失眠的病因后仍遗留失眠症状，主要包括心理生理性失眠、特发性失眠和主观性失眠3种类型。原发性失眠的诊断缺乏特异性指标，主要是一种排除性诊断。当可能引起失眠的病因被排除或治愈以后，仍遗留失眠症状时即可考虑为原发性失眠。心理生理性失眠在临床上发现其病因都可以溯源为某一个或长期事件对患者大脑边缘***功能稳定性的影响，边缘***功能的稳定性失衡最终导致了大脑睡眠功能的紊乱，失眠发生。继发性失眠包括由于躯体疾病、精神障碍、药物滥用等引起的失眠，以及与睡眠呼吸紊乱、睡眠运动障碍等相关的失眠。失眠常与其他疾病同时发生，有时很难确定这些疾病与失眠之间的因果关系，故近年来提出共病性失眠(comorbidinsomnia)的概念，用以描述那些同时伴随其他疾病的失眠。
失眠患者的临床表现主要有以下方面：1.睡眠过程的障碍，入睡困难、睡眠质量下降和睡眠时间减少；2.日间认知功能障碍，记忆功能下降、注意功能下降、计划功能下降从而导致白天困倦，工作能力下降，在停止工作时容易出现日间嗜睡现象；3.大脑边缘***及其周围的植物神经功能紊乱；4.其他***症状，容易出现短期内体重减低，免疫功能减低和内分泌功能紊乱。失眠往往会给患者带来极大的痛苦和心理负担，又会因为滥用失眠药物而损伤身体其他方方面面。
目前失眠主要的干预措施是药物治疗。尽管具有催眠作用的药物种类繁多，但其中大多数药物的主要用途并不是治疗失眠。目前临床治疗失眠的药物主要包括苯二氮卓类受体激动剂(benzodiazepinereceptoragonists,BZRAs)、褪黑素受体激动剂和具有催眠效果的抗抑郁药物。抗组胺药物(如苯海拉明)、褪黑素以及缬草提取物虽然具有催眠作用，但是现有的临床研究证据有限，不宜作为失眠常规用药。一般的治疗推荐：艾司佐匹克隆(eszopiclone)、唑吡坦、唑吡坦控释剂(zolpidem-CR)、佐匹克隆(zopiclone)。治疗失眠的药物复杂而且繁多，包括艾司***(estazolam)，氟西泮(flurazepam)、夸西泮(quazepam)、替马西泮(temazepam)、***仑(triazolam)、阿普***(alprazolam)、氯氮卓(chlordiazepoxide)、地西伴(diazepam)、劳拉西伴(lorazepam)、咪哒***(midazolam)、唑吡坦、唑吡坦控释剂(zolpidem-CR)、佐匹克隆(zopiclone)、右佐匹克隆(eszopiclone)和扎来普隆(zaleplon)、雷美尔通(ramelteon)、特斯美尔通(Ⅲ期临床中，tasimelteon)、阿戈美拉汀(agomelatin)、三环类抗抑郁药物、选择性5-色胺再摄取抑制剂(SSRIs)、5-羟色胺和去甲肾上腺素再摄取抑制(SNRIs)、小剂量米氮平、小剂量曲唑酮等。由于有些药物有依赖的可能性，所以，一般不宜长期服用。
发明内容
有鉴于此，本发明的目的在于针对现有技术中存在的问题，提供一种供失眠人群食用的含肽组合物及其应用。
为实现本发明的目的，本发明采用如下技术方案：
一种供失眠人群食用的含肽组合物，由牛骨低聚肽粉、酸枣仁粉、黑芝麻粉、龙眼肉粉、核桃低聚肽粉组成。
作为优选，以重量份计，牛骨低聚肽粉2份-5份、酸枣仁粉0.5份-1份、黑芝麻粉0.5份-1份、龙眼肉粉0.5份-1份、核桃低聚肽粉1份-3份。
在一些实施方案中，所述含肽组合物还包括辅料，所述辅料为食用香精、甜味剂、复合维生素中的至少一种。即所述含肽组合物可以添加或不添加食用香精、甜味剂或复合维生素。
进一步，作为优选，所述含肽组合物中，以重量份计，食用香精0.01份-0.5份，甜味剂0.01份-0.5份，复合维生素0.01份-0.2份。
在一些实施方案中，以重量份计，所述含肽组合物由牛骨低聚肽粉2份、酸枣仁粉1份、黑芝麻粉0.5份、龙眼肉粉1份、核桃低聚肽粉1份组成。
在一些实施方案中，以重量份计，所述含肽组合物由牛骨低聚肽粉5份、酸枣仁粉0.5份、黑芝麻1份、龙眼肉粉0.5份、核桃低聚肽粉3份、复合维生素0.2份组成。
在一些实施方案中，以重量份计，所述含肽组合物由牛骨低聚肽粉2份、酸枣仁粉0.5份、黑芝麻粉0.5份、龙眼肉粉0.5份、核桃低聚肽粉1份、甜味剂0.5份、复合维生素0.01份组成。
在一些实施方案中，以重量份计，所述含肽组合物由牛骨低聚肽粉5份、酸枣仁粉1份、黑芝麻粉1份、龙眼肉粉1份、核桃低聚肽粉3份、食用香精0.01份、甜味剂0.01份、复合维生素0.2份组成。
本发明所述含肽组合物中的各成分均可以通过商业渠道购买得到。
在一些实施方案中，所述牛骨低聚肽粉由以下制备方法制备获得：以新鲜牛骨为原料，依次经破碎、清洗、高压提取、复合蛋白酶酶解、过滤、浓缩工艺加工，添加或不添加食品添加剂柠檬酸、食品用香精，经混合、干燥，制作而成牛骨低聚肽粉。
在一些实施方案中，所述核桃低聚肽粉由以下制备方法制备获得：
以鲜核桃为原料，经高压提取、复合酶酶解、过滤、浓缩、干燥，制作而成核桃低聚肽粉。
本发明所述组合物具有宁心安神的功效，改善心悸不安、失眠方面效果显著。因此本发明提供了所述组合物在制备辅助改善心悸不安、失眠的产品中的应用。
本发明所述组合物以牛骨低聚肽粉、酸枣仁粉、黑芝麻粉、龙眼肉粉、核桃低聚肽粉为主要成分，辅以辅料制备成一种供失眠人群食用的含肽组合物，所述组合物具有宁心安神的功效，改善心悸不安、失眠方面的效果显著，可用于制备辅助改善心悸不安、失眠的产品。
具体实施方式
本发明公开了一种供失眠人群食用的含肽组合物及其应用。本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明的方法及产品已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法进行改动或适当变更与组合，来实现和应用本发明技术。
为了进一步理解本发明，下面将结合本发明实施例，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于本发明保护的范围。
如无特殊说明，本发明实施例中所涉及的试剂均为市售产品，均可以通过商业渠道购买获得。
实施例1：本发明所述含肽组合物
由牛骨低聚肽粉2份、酸枣仁粉1份、黑芝麻粉0.5份、龙眼肉粉1份、核桃低聚肽粉1份混合组成。
实施例2：本发明所述含肽组合物
由牛骨低聚肽粉5份、酸枣仁粉0.5份、黑芝麻1份、龙眼肉粉0.5份、核桃低聚肽粉3份、复合维生素0.2份混合组成。
实施例3：本发明所述含肽组合物
由牛骨低聚肽粉2份、酸枣仁粉0.5份、黑芝麻粉0.5份、龙眼肉粉0.5份、核桃低聚肽粉1份、甜味剂0.5份、复合维生素0.01份混合组成。
实施例4：本发明所述含肽组合物
由牛骨低聚肽粉5份、酸枣仁粉1份、黑芝麻粉1份、龙眼肉粉1份、核桃低聚肽粉3份、食用香精0.01份、甜味剂0.01份、复合维生素0.2份混合组成。
试验例：
1、临床实验观察：
本发明对300例患者进行临床观察，患者为男女各年龄段，均为失眠相关疾病，表现为心悸不安、无法入睡、睡眠质量差等。服用方法：口服本发明实施例1的含肽组合物，一日两至三次，连续服用二个月至半年。
其中，评定标准：
治愈：失眠的临床表现消失。
好转：失眠的临床表现明显好转或好转。
无效：失眠的临床表现没有改善，未见好转。
效果：服用本发明所述含肽组合物有效率91.5％，治愈率39.5％，好转率52％，无效8.5％。
本发明实施例2-4所述的含肽组合物效果与实施例1所述含肽组合物效果相当，有效率＞90％。
2、典型案例
张先生，60多岁，睡眠质量不好，睡觉特别轻，而且经常夜里发慌，恐惧，容易醒，服用实施例2所述含肽组合物3个月后，睡眠质量改善很多，有时候还经常一觉到天亮。
李女士，50多岁，睡眠质量不好，经常睡觉时间特别长，但是总是困，而且每天特别累，总想睡觉，服用实施例2所述含肽组合物不到半年，睡觉特别踏实，而且起来后比较有精神，现在睡眠有规律多了。
上述实施例的说明只是用于理解本发明的方法及其核心思想。应当指出，对于本领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以对本发明进行若干改进和修饰，这些改进和修饰也将落入本发明权利要求的保护范围内。
Claims (7)
1.一种供失眠人群食用的含肽组合物，其特征在于，由牛骨低聚肽粉、酸枣仁粉、黑芝麻粉、龙眼肉粉、核桃低聚肽粉组成。
2.根据权利要求1所述含肽组合物，其特征在于，以重量份计，牛骨低聚肽粉2份-5份、酸枣仁粉0.5份-1份、黑芝麻粉0.5份-1份、龙眼肉粉0.5份-1份、核桃低聚肽粉1份-3份。
3.根据权利要求1所述含肽组合物，其特征在于，还包括辅料，所述辅料为食用香精、甜味剂、复合维生素中的至少一种。
4.根据权利要求3所述含肽组合物，其特征在于，以重量份计，食用香精0.01份-0.5份，甜味剂0.01份-0.5份，复合维生素0.01份-0.2份。
5.根据权利要求1所述含肽组合物，其特征在于，所述牛骨低聚肽粉由以下制备方法制备获得：
以新鲜牛骨为原料，依次经破碎、清洗、高压提取、复合蛋白酶酶解、过滤、浓缩工艺加工，添加或不添加食品添加剂柠檬酸、食品用香精，经混合、干燥，制作而成牛骨低聚肽粉。
6.根据权利要求1所述含肽组合物，其特征在于，所述核桃低聚肽粉由以下制备方法制备获得：
以鲜核桃为原料，经高压提取、复合酶酶解、过滤、浓缩、干燥，制作而成核桃低聚肽粉。
7.权利要求1-6任意一项所述含肽组合物在制备辅助改善心悸不安、失眠的产品中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911061567.9A CN110663959A (zh) | 2019-11-01 | 2019-11-01 | 一种供失眠人群食用的含肽组合物及应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911061567.9A CN110663959A (zh) | 2019-11-01 | 2019-11-01 | 一种供失眠人群食用的含肽组合物及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110663959A true CN110663959A (zh) | 2020-01-10 |
Family
ID=69085632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911061567.9A Pending CN110663959A (zh) | 2019-11-01 | 2019-11-01 | 一种供失眠人群食用的含肽组合物及应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110663959A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112056482A (zh) * | 2020-10-13 | 2020-12-11 | 广州小象健康产业有限公司 | 一种助眠小分子肽固体饮料及其制备方法和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104738624A (zh) * | 2015-03-17 | 2015-07-01 | 鄢明亮 | 一种神经衰弱、健忘失眠的营养保健食品 |
| CN105476030A (zh) * | 2015-12-15 | 2016-04-13 | 北京天肽生物科技有限公司 | 一种多功能复合低聚肽营养粉 |
| CN105995425A (zh) * | 2016-05-16 | 2016-10-12 | 广州市好孝心医疗器械有限公司 | 一种药食同源的具有改善睡眠功能的组合物及其应用 |
| WO2017005220A1 (zh) * | 2015-07-09 | 2017-01-12 | 杨高林 | 用于治疗心律失常的中药组合物及其制备方法 |
| EP3141255A1 (en) * | 2015-09-10 | 2017-03-15 | Infinitus (China) Company Ltd. | Memory improving composition, preparation method and use thereof |
| CN110279842A (zh) * | 2019-07-05 | 2019-09-27 | 辽宁太爱肽生物工程技术有限公司 | 一种解酒护肝组合物及其应用 |
-
2019
- 2019-11-01 CN CN201911061567.9A patent/CN110663959A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104738624A (zh) * | 2015-03-17 | 2015-07-01 | 鄢明亮 | 一种神经衰弱、健忘失眠的营养保健食品 |
| WO2017005220A1 (zh) * | 2015-07-09 | 2017-01-12 | 杨高林 | 用于治疗心律失常的中药组合物及其制备方法 |
| EP3141255A1 (en) * | 2015-09-10 | 2017-03-15 | Infinitus (China) Company Ltd. | Memory improving composition, preparation method and use thereof |
| CN105476030A (zh) * | 2015-12-15 | 2016-04-13 | 北京天肽生物科技有限公司 | 一种多功能复合低聚肽营养粉 |
| CN105995425A (zh) * | 2016-05-16 | 2016-10-12 | 广州市好孝心医疗器械有限公司 | 一种药食同源的具有改善睡眠功能的组合物及其应用 |
| CN110279842A (zh) * | 2019-07-05 | 2019-09-27 | 辽宁太爱肽生物工程技术有限公司 | 一种解酒护肝组合物及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| 刘云芳等: "药食两用复方颗粒剂治疗心神失养型亚健康失眠的临床研究", 《广州中医药大学学报》 * |
| 李鹏等: "失眠多梦――养心宁神粉", 《蜜蜂杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112056482A (zh) * | 2020-10-13 | 2020-12-11 | 广州小象健康产业有限公司 | 一种助眠小分子肽固体饮料及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tan et al. | Intrathecal bupivacaine with morphine or neostigmine for postoperative analgesia after total knee replacement surgery | |
| US10335447B2 (en) | Solid beverage for conditioning Qi deficiency constitution and method for producing the same | |
| KR20130073938A (ko) | 관상 동맥성 심장병의 ２차 예방을 위한 약의 조제에 있어서 단삼 조성물의 용도 | |
| CN111135285A (zh) | 火麻仁安神助眠组合物及其制备方法和应用 | |
| Eccles | Central mechanisms IV: conscious control of cough and the placebo effect | |
| US10172899B2 (en) | Composition for preventing, treating and improving of voiding dysfunction comprising extract from Piper longum L | |
| CN104382050B (zh) | 一种宁心安神、助睡眠的保健品 | |
| CN104256632A (zh) | 一种改善睡眠的保健品 | |
| CN112294924A (zh) | 一种养心安神药物组合物及其制备方法和应用 | |
| CN110663959A (zh) | 一种供失眠人群食用的含肽组合物及应用 | |
| CN104223073B (zh) | 一种助眠的食品、保健品或药物组合物 | |
| CN107334954B (zh) | 一种治疗帕金森病的中药组合物及其制备方法 | |
| CN113244303B (zh) | 一种治疗原发性头痛的药物组合物及其制备方法 | |
| Ardizzone et al. | Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials | |
| CN114377109A (zh) | 一种安神助眠组合物及其制备方法和应用 | |
| CN109464527B (zh) | 组合物及其制备方法和应用、保健品和改善睡眠的药物 | |
| US10561694B2 (en) | Pharmaceutical compositions containing cannabis, uses thereof and methods for improving sleep quality | |
| CN107050163A (zh) | 具有改善睡眠质量作用的中药组合物、制剂及其制备方法 | |
| CN112603948A (zh) | 一种治疗失眠症的药物及其制备方法 | |
| US10376566B2 (en) | Composition and method for improving sleep duration and quality | |
| CN114081175A (zh) | 一种组合物及其在制备改善睡眠的产品中的应用 | |
| CN111453831A (zh) | 一种改善睡眠质量的饮用水 | |
| KR20120055159A (ko) | 감국 추출물을 포함하는 불면 증상의 예방 및 개선용 조성물과 그의 제조방법 | |
| CN107837331A (zh) | 一种治疗失眠的中药组合物及其制备方法 | |
| KR101568044B1 (ko) | 불안 및 스트레스 해소용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200110 |
|
| RJ01 | Rejection of invention patent application after publication |